Tag: Dr. Jeff Popma


Study Shows High-Risk PCI with Impella Improved 90-day Event-Free Survival Compared to IABP

Article

Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessen BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman EM, Stone GW, O’Neill WW. Impact of Hemodynamic Support with Impella 2.5 versus Intra Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). Am J Cardiol 2014;113:222-228.

Objective

To compare clinical outcomes resulting from the use of the Impella 2.5 heart pump to those of the intra aortic balloon pump (IABP) during high-risk PCI.Continue readingStudy Shows High-Risk PCI with Impella Improved 90-day Event-Free Survival Compared to IABP

Real-World Data Show Protected PCI Patients Had Significant CHF Symptom Improvement at Discharge

Article

 publication-highlight-real-world-vs-clinical-trial-experience-with-impella-for-high-risk-pciThe abstract for this article was presented by Dr. Mauricio Cohen at TCT 2015 and reported by the Protected PCI blogging team during the conference.

Objective

Cohen, et al. (2015) compared the experiences of high-risk PCI patients in the PROTECT II clinical trial with a similar group of patients treated in certain “real world” clinical settings. Patients enrolled in the now global cVAD Registry™ (formerly USpella) comprised the “real world” patient groups.Continue readingReal-World Data Show Protected PCI Patients Had Significant CHF Symptom Improvement at Discharge

Roundtable Discusses the Growing Need for Protected PCI

There is a growing need in the cath lab to treat more high risk patients, per the CHIP initiative. Dr. Ajay Kirtane, Dr. John Lasala, Dr. Jeff Popma and Dr. Jeff Moses discuss. Subscribe or join the conversation by following us on Twitter: @ProtectedPCI IMP-820-16